Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve

{
  "signal_id": "0c259890-e0e8-3bee-9a36-98e3b8b00d9c",
  "signal_type": "news",
  "signal_subtype": "has_revenue",
  "detected_at": "2026-10-02T14:46:02+00:00",
  "company": {
    "name": "Edwards Lifesciences",
    "domain": "edwards.com"
  },
  "data": {
    "url": "https://www.benzinga.com/news/health-care/26/10/62136843/edwards-lifesciences-secures-fda-approval-for-first-expandable-pediatric-heart-valve",
    "title": "Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart Valve - Benzinga",
    "excerpt": "Edwards Lifesciences Corp. (NYSE: EW ) on Thursday gained U.S. Food and Drug Administration clearance for its AUTUS Size-Adjustable Valve, offering a specialized surgical option for pediatric patients needing pulmonary valve replacement due to congenital heart disease. The newly approved medical device addresses a critical healthcare gap by expanding inside a growing child’s body through a minimally invasive transcatheter procedure, potentially sparing young patients from multiple open-heart surgeries. The device starts at an initial implant size of roughly 13 millimeters - suitable for toddlers and preschool-aged children - and expands up to 22 millimeters using a balloon catheter. This upper limit matches standard adult pulmonary valve dimensions. Unlike conventional heart valves that rely on animal tissue susceptible to premature hardening and degradation in pediatric patients, the AUTUS valve incorporates synthetic polymeric leaflets. Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue. EW stock jumps as analysts see continued upside ahead. The FDA approval marks the first time a valve utilizing polymeric leaflet material has received clearance for any medical application . One-year follow-up clinical data indicate these synthetic components maintain structural integrity over time. Regulatory approval is based on comprehensive clinical trial evidence...",
    "summary": "Edwards Lifesciences reported Q2 revenue of $1.74 billion, exceeding Wall Street estimates.",
    "planning": false,
    "image_url": "https://cdn.benzinga.com/cdn-cgi/image/width=1200,height=800,fit=crop/files/images/story/2026/10/02/Doctors--Tablet-And-People-With-Discussi.jpg",
    "confidence": 0.9,
    "published_at": "2026-10-02T14:46:02Z",
    "article_sentence": "Edwards Lifesciences tops Q2 Wall Street estimates with $1.74B in revenue.",
    "amount_normalized": 1740000000
  }
}

curl https://signals.autobound.ai/v1/signals/0c259890-e0e8-3bee-9a36-98e3b8b00d9c \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"edwards.com","limit":20}'